Market research
LUMO Lumos Pharma Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 38M
- P/E ratio
- Not available
- Analyst target
- 4.25
- Dividend yield
- Not available
- Beta
- 0.33
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US55028X1090
- Market cap
- 38M
- P/E ratio
- Not available
- Analyst target
- 4.25
- Dividend yield
- Not available
- Beta
- 0.33
About
About Lumos Pharma Inc
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas. As of December 12, 2024, Lumos Pharma, Inc. was taken private.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the LUMO discussion.
5 years, 4 months ago
Lumos Pharma, Inc is currently in a long term downtrend where the price is trading 35.1% below its 200 day moving average.
From a valuation standpoint, the stock is 63.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 494.2.
Lumos Pharma, Inc's total revenue sank by 90.8% to $40K since the same quarter in the previous year.
Its net income has increased by 70.8% to $-2M since the same quarter in the previous year.
Finally, its free cash flow grew by 12.9% to $-7M since the same quarter in the previous year.
Based on the above factors, Lumos Pharma, Inc gets an overall score of 3/5.